Chandra Bhagat Pharma (BOM:542934) EBIT: ₹61 Mil (TTM As of Mar. 2026)


BOM:542934 Chandra Bhagat Pharma Ltd BOM:542934
69 GF Score
Price ₹44.80
GF Value ₹70.22
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Chandra Bhagat Pharma EBIT?

Chandra Bhagat Pharma BOM:542934 +1.80% 69 EBIT is ₹61 Mil as of Mar. 2026. GuruFocus rates BOM:542934 with a GF Score™ of 69/100 and a GF Value™ of ₹70.22 (Possible Value Trap). The stock has 4 warning signs investors should review.

Chandra Bhagat Pharma's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chandra Bhagat Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 3.55%. Chandra Bhagat Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 87.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Chandra Bhagat Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.42%.


Chandra Bhagat Pharma  (BOM:542934) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chandra Bhagat Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=34.008 * ( 1 - 26.2% )/( (837.242 + 575.415)/ 2 )
=25.097904/706.3285
=3.55 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=942.058 - 318.851 - ( 47.792 - max(0, 584.823 - 876.695+47.792))
=575.415

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Chandra Bhagat Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=94.266/( ( (20.425 + max(-16.203, 0)) + (26.242 + max(168.019, 0)) )/ 2 )
=94.266/( ( 20.425 + 194.261 )/ 2 )
=94.266/107.343
=87.82 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(300.674 + 33.439 + 16.083) - (19.048 + 0 + 347.351)
=-16.203

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(546.17 + 46.721 + 20.559) - (318.851 + 0 + 126.58)
=168.019

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Chandra Bhagat Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=61.08/455.300
=13.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chandra Bhagat Pharma EBIT Related Terms


Chandra Bhagat Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Chandra Bhagat Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chandra Bhagat Pharma EBIT Chart

Chandra Bhagat Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.80 33.37 35.49 31.13 61.08

Chandra Bhagat Pharma Semi-Annual Data
Mar17 Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.69 14.59 16.54 13.95 47.13

BOM:542934 vs MCK, CAH, COR: EBIT Comparison

For the Medical Distribution subindustry, Chandra Bhagat Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chandra Bhagat Pharma EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chandra Bhagat Pharma's EV-to-EBIT falls into.


BOM:542934
69GF Score
Chandra Bhagat Pharma Ltd BOM:542934
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chandra Bhagat Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹61 Mil mean?
Chandra Bhagat Pharma (BOM:542934) has a EBIT of ₹61 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chandra Bhagat Pharma.
Is Chandra Bhagat Pharma's EBIT too high?
Chandra Bhagat Pharma's current EBIT is ₹61 Mil. Overall, Chandra Bhagat Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's EBIT compare to MCK and CAH?
Chandra Bhagat Pharma's EBIT of ₹61 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chandra Bhagat Pharma. Chandra Bhagat Pharma's current EBIT is ₹61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.22, compared to a current price of ₹44.80 — trading 36.2% below its estimated fair value. The current EBIT is ₹61 Mil. Chandra Bhagat Pharma's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current EBIT is ₹61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?

Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued. The current stock price of ₹44.80 is trading 36.2% below its estimated GF Value™ of ₹70.22. GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.

Key valuation signals for BOM:542934:

  • EBIT: ₹61 Mil
  • GF Value™: ₹70.22 vs. price of ₹44.80 (36.2% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chandra Bhagat Pharma Business Description

Address Doctor Ambedkar Road, 323-F, Flat 1,2, Bhagat Bhuvan, Matunga East, Mumbai, MH, IND, 400019
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
69GF Score

Get the complete analysis for BOM:542934

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹44.80
Price
₹70.22
GF Value